Results 11 to 20 of about 29,210 (297)

RETRACTED ARTICLE: Ibrutinib facilitates the sensitivity of colorectal cancer cells to ferroptosis through BTK/NRF2 pathway

Cell Death and Disease, 2023
Ibrutinib is a drug that inhibits the protein Burton’s tyrosine kinase and thereby the nuclear translocation of Nrf2, which played a key role in mediating the activation of antioxidants during stress conditions and ferroptosis resistance.
Jin-Feng Zhu, Yi Liu, Wen-Ting Li, Ming-Hui Li, Chao-Hui Zhen, Pei-Wei Sun, Ji-Xin Chen, Wen-Hao Wu, Wei Zeng   +8 more
doaj   +2 more sources

Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells [PDF]

Brazilian Journal of Medical and Biological Research
Despite the widespread use of R-CHOP therapy in diffuse large B-cell lymphoma (DLBCL), the therapeutic efficacy for this disease remains suboptimal, primarily due to the heterogeneity of refractory and/or relapsed diseases.
Fengbo Jin, Limei He, Yingying Chen, Wanlu Tian, Lixia Liu, Ling Ge, Wei Qian, Leiming Xia, Mingzhen Yang   +8 more
doaj   +3 more sources

Arrhythmia Patterns in Patients on Ibrutinib [PDF]

Frontiers in Cardiovascular Medicine, 2022
Introduction: Ibrutinib, a Bruton's tyrosine kinase inhibitor (TKI) used primarily in the treatment of hematologic malignancies, has been associated with increased incidence of atrial fibrillation (AF), with limited data on its association with other ...
Muhammad Fazal, Ridhima Kapoor, Paul Cheng, Albert J. Rogers, Sanjiv M. Narayan, Paul Wang, Ronald M. Witteles, Alexander C. Perino, Tina Baykaner, June-Wha Rhee   +9 more
doaj   +3 more sources

Ibrutinib [PDF]

Australian Prescriber, 2015

openalex   +3 more sources

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia [PDF]

New England Journal of Medicine, 2015
Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Nancy L. Bartlett, Jianyong Li, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen O. McCarthy, Steven Coutré, Hang Quach, Gianluca Gaïdano, Zvenyslava Maslyak, Don A. Stevens, Ann Janssens, Fritz Offner, Jiřı́ Mayer, Michael O’Dwyer, Andrzej Hellmann, Anna Schuh, Tanya Siddiqi, Aaron Polliack, Constantine S. Tam, Deepali Suri, Mei Cheng, Fong Clow, Lori Styles, Danelle F. James, Thomas J. Kipps   +33 more
openalex   +2 more sources

Extrahepatic metabolism of ibrutinib [PDF]

Investigational New Drugs, 2020
SummaryIbrutinib is a first-in-class Bruton’s kinase inhibitor used in the treatment of multiple lymphomas. In addition to CYP3A4-mediated metabolism, glutathione conjugation can be observed. Subsequently, metabolism of the conjugates and finally their excretion in feces and urine occurs. These metabolites, however, can reach substantial concentrations
Rosalinde Masereeuw, Rolf W. Sparidans, Alfred H. Schinkel, Amer Jamalpoor, Roeland E Wasmann, Roeland E Wasmann, Manoe J. Janssen, Jos H. Beijnen, Jos H. Beijnen, Matthijs J. van Haren, Matthijs J. van Haren, Stephanie van Hoppe, Stephanie van Hoppe, Johannes J.M. Rood   +13 more
openaire   +5 more sources

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.

New England Journal of Medicine, 2022
BACKGROUND In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic ...
Jennifer R. Brown, B. Eichhorst, P. Hillmen, W. Jurczak, M. Kaźmierczak, N. Lamanna, S. O'brien, C. Tam, L. Qiu, K. Zhou, M. Šimkovič, J. Mayer, A. Gillespie-Twardy, A. Ferrajoli, P. Ganly, R. Weinkove, S. Grosicki, A. Mital, T. Robak, A. Osterborg, H. Yimer, T. Salmi, M. Wang, L. Fu, Jessica Li, Kenneth Wu, A. Cohen, M. Shadman   +27 more
semanticscholar   +1 more source

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

Journal of Clinical Oncology, 2021
PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability.
J. Byrd, P. Hillmen, P. Ghia, A. Kater, A. Chanan-Khan, R. Furman, S. O'brien, M. Yenerel, Á. Illés, N. Kay, J. García-Marco, A. Mato, J. Pinilla-Ibarz, J. Seymour, S. Leprêtre, S. Stilgenbauer, T. Robak, Wayne Rothbaum, R. Izumi, A. Hamdy, P. Patel, K. Higgins, S. Sohoni, W. Jurczak   +23 more
semanticscholar   +1 more source

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

Journal of Clinical Oncology, 2023
The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM). Here, we report long-term follow-up outcomes from ASPEN.
M. Dimopoulos, Stephen Samuel Opat, S. D’Sa, W. Jurczak, Hui-Peng Lee, G. Cull, R. Owen, P. Marlton, B. Wahlin, R. García-Sanz, H. McCarthy, S. Mulligan, A. Tedeschi, J. Castillo, J. Czyż, C. Fernández de Larrea, D. Belada, E. Libby, J. Matous, M. Motta, T. Siddiqi, M. Tani, M. Trněný, M. Minnema, C. Buske, V. Leblond, S. Treon, J. Trotman, W. Chan, J. Schneider, H. Allewelt, S. Patel, A. Cohen, C. Tam   +33 more
semanticscholar   +1 more source

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

Blood Advances, 2023
Key Points • One-third of patients with CLL relapsing on ibrutinib do not carry BTK/PLCG2 mutations, even with a 0.1% sensitivity.• Additional mechanisms, such as del(8p), EGR2 and NF-κB pathway mutations, may be cooperating in determining progression on
S. Bonfiglio, L. Sutton, V. Ljungström, A. Capasso, Tatjana Pandzic, Simone Weström, H. Foroughi-Asl, A. Skaftason, A. Gellerbring, Anna Lyander, F. Gandini, G. Gaidano, L. Trentin, L. Bonello, G. Reda, Csaba Bödör, N. Stavroyianni, C. Tam, R. Marasca, F. Forconi, P. Panayiotidis, I. Ringshausen, O. Jakšić, A. Frustaci, S. Iyengar, M. Coscia, S. Mulligan, L. Ysebaert, V. Strugov, C. Pavlovsky, R. Walewska, A. Österborg, D. Cortese, P. Ranghetti, P. Baliakas, K. Stamatopoulos, L. Scarfò, R. Rosenquist, P. Ghia   +38 more
semanticscholar   +1 more source